Pharma Equity Group A/S (PEG.CO)
DKK 0.18
(-2.17%)
DKK 0.18
(-2.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 25.99 Million DKK | 14.7% |
| 2022 | 22.65 Million DKK | 19.73% |
| 2021 | 18.92 Million DKK | 88.48% |
| 2020 | 10.04 Million DKK | 504.52% |
| 2019 | 1.66 Million DKK | 11.85% |
| 2018 | 1.48 Million DKK | 1385.0% |
| 2017 | 100 Thousand DKK | -98.6% |
| 2016 | 7.14 Million DKK | -68.7% |
| 2015 | 22.83 Million DKK | 175538.46% |
| 2014 | 13 Thousand DKK | -100.0% |
| 2013 | 301.65 Million DKK | 62.0% |
| 2012 | 186.2 Million DKK | 0.74% |
| 2011 | 184.84 Million DKK | -22.09% |
| 2010 | 237.24 Million DKK | 9961.28% |
| 2009 | 2.35 Million DKK | -98.79% |
| 2008 | 195.58 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 43.01 Million DKK | 16.24% |
| 2024 Q1 | 37 Million DKK | 42.38% |
| 2023 Q2 | 17.99 Million DKK | 95.83% |
| 2023 Q1 | 9.19 Million DKK | -59.44% |
| 2023 Q3 | 21.19 Million DKK | 17.75% |
| 2023 FY | 25.99 Million DKK | 14.7% |
| 2023 Q4 | 25.99 Million DKK | 22.64% |
| 2022 Q2 | 20.57 Million DKK | 0.0% |
| 2022 FY | 22.65 Million DKK | 19.73% |
| 2022 Q4 | 22.65 Million DKK | 0.0% |
| 2021 FY | 18.92 Million DKK | 88.48% |
| 2021 Q4 | 18.92 Million DKK | 0.0% |
| 2021 Q2 | 8.33 Million DKK | 0.0% |
| 2020 Q4 | 10.04 Million DKK | 0.0% |
| 2020 FY | 10.04 Million DKK | 504.52% |
| 2020 Q2 | 3.63 Million DKK | 0.0% |
| 2019 Q4 | 1.66 Million DKK | 0.0% |
| 2019 Q2 | 995 Thousand DKK | 0.0% |
| 2019 FY | 1.66 Million DKK | 11.85% |
| 2018 Q4 | 1.48 Million DKK | 0.0% |
| 2018 FY | 1.48 Million DKK | 1385.0% |
| 2018 Q2 | 1.4 Million DKK | 0.0% |
| 2017 Q2 | 5.5 Million DKK | 0.0% |
| 2017 FY | 100 Thousand DKK | -98.6% |
| 2017 Q4 | 100 Thousand DKK | 0.0% |
| 2016 Q2 | 5.1 Million DKK | 4.29% |
| 2016 FY | 7.14 Million DKK | -68.7% |
| 2016 Q1 | 4.89 Million DKK | -78.57% |
| 2015 Q2 | 1.43 Million DKK | 31.77% |
| 2015 Q4 | 22.83 Million DKK | 310.74% |
| 2015 Q1 | 1.08 Million DKK | 8276.92% |
| 2015 FY | 22.83 Million DKK | 175538.46% |
| 2015 Q3 | 5.55 Million DKK | 287.39% |
| 2014 Q4 | 13 Thousand DKK | -99.98% |
| 2014 Q3 | 72.38 Million DKK | 0.37% |
| 2014 FY | 13 Thousand DKK | -100.0% |
| 2014 Q1 | 16.19 Million DKK | -94.63% |
| 2014 Q2 | 72.11 Million DKK | 345.31% |
| 2013 Q2 | 188.05 Million DKK | -18.86% |
| 2013 FY | 301.65 Million DKK | 62.0% |
| 2013 Q3 | 169.24 Million DKK | -10.0% |
| 2013 Q4 | 301.65 Million DKK | 78.23% |
| 2013 Q1 | 231.76 Million DKK | 24.47% |
| 2012 Q3 | 179.3 Million DKK | -44.31% |
| 2012 FY | 186.2 Million DKK | 0.74% |
| 2012 Q4 | 186.2 Million DKK | 3.85% |
| 2012 Q1 | 322.59 Million DKK | 74.53% |
| 2012 Q2 | 321.98 Million DKK | -0.19% |
| 2011 Q2 | 345.84 Million DKK | 0.75% |
| 2011 FY | 184.84 Million DKK | -22.09% |
| 2011 Q3 | 222.1 Million DKK | -35.78% |
| 2011 Q4 | 184.84 Million DKK | -16.78% |
| 2011 Q1 | 343.27 Million DKK | 44.69% |
| 2010 FY | 237.24 Million DKK | 9961.28% |
| 2010 Q2 | 24.74 Million DKK | 0.0% |
| 2010 Q3 | 26.99 Million DKK | 9.08% |
| 2010 Q4 | 237.24 Million DKK | 778.82% |
| 2009 FY | 2.35 Million DKK | -98.79% |
| 2009 Q4 | 2.35 Million DKK | 0.0% |
| 2008 FY | 195.58 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 291 Million DKK | 91.069% |
| Bavarian Nordic A/S | -1.33 Billion DKK | 101.951% |
| Genmab A/S | -14.09 Billion DKK | 100.184% |
| Gubra A/S | 18.03 Million DKK | -44.085% |
| Novo Nordisk A/S | 12.61 Billion DKK | 99.794% |
| Orphazyme A/S | -11.26 Million DKK | 330.633% |
| Zealand Pharma A/S | -249.03 Million DKK | 110.436% |